A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells

Journal of Cellular Physiology

Volumn 229, Issue 12, 2014, Pages 2106-2116

  Leotta, Marzia ^a   Biamonte, Lavinia ^a   Raimondi, Lavinia ^a   Ronchetti, Domenica ^b   Di Martino, Maria Teresa ^a   Botta, Cirino ^a   Leone, Emanuela ^a   Pitari, Maria Rita ^a   Neri, Antonino ^b,c   Giordano, Antonio ^d,e   Tagliaferri, Pierosandro ^a   Tassone, Pierfrancesco ^a,e   Amodio, Nicola ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 125A 5P; MICRORNA 192; MICRORNA 194; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE MARROW STROMA CELL; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

3' UNTRANSLATED REGIONS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; MULTIPLE MYELOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906691556     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24669     Document Type: Article

References (98)

1. Abdi J, Chen G, Chang H. 2013. Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms. Oncotarget 4:2186-2207.
2. Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R, Botti G, Pirozzi P, Rocco G, De Rosa N, Viglietto G. 2010. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol 177:2622-2634.
3. Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gulla AM, Pitari MR, Conforti F, Rossi M, Agosti V, Fulciniti M, Misso G, Morabito F, Ferrarini M, Neri A, Caraglia M, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. 2012a. MiR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 3:e436.
4. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gulla AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P, Tassone P. 2012b. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 3:1246-1258.
5. Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, D'Aquila P, Di Martino MT, Calimeri T, Rossi M, Lionetti M, Leone E, Passarino G, Neri A, Giordano A, Tagliaferri P, Tassone P. 2013a. MiR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle 12:3650-3662.
6. Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P. 2013b. Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther 13:S125-S137.
7. Avet-Loiseau H, Li JY, Godon C, Morineau N, Daviet A, Harousseau JL, Facon T, Bataille R. 1999. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol 106:717-719.
8. Bartel DP. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
9. Benetatos L. 2013. MiR-29b: A new demethylator in multiple myeloma. Cell Cycle 12:3718-3719.
10. Bi Y, Liu G, Yang R. 2009. MicroRNAs: Novel regulators during the immune response. J Cell Physiol 218:467-472.
11. Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, Jin J, Liang S, Chen Z, Xu G, Nie Y, Wu K, Liu J, Shi Y, Ding J, Fan D. 2012. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PloS ONE 7:e40169.
12. Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. 2012. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood 120:5002-5013.
13. Burns TF, El-Deiry WS. 1999. The p53 pathway and apoptosis. J Cell Physiol 181:231-239.
14. Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, Rossi M, Foresta U, Piro E, Ferrara F, Amorosi A, Bahlis N, Anderson KC, Munshi N, Tagliaferri P, Causa F, Tassone P. 2011. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 25:707-711.
15. Chen D, Farwell MA, Zhang B. 2010. MicroRNA as a new player in the cell cycle. J Cell Physiol 225:296-301.
16. Chi J, Ballabio E, Chen XH, Kusec R, Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Lawrie CH. 2011. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 6:23.
17. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B, Greipp P, Rajkumar SV, Fonseca R. 2007. Clinical significance of TP53 mutation in myeloma. Leukemia 21:582-584.
18. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. 2001. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19:1405-1413.
19. Chu CY, Rana TM. 2007. Small RNAs: Regulators and guardians of the genome. J Cell Physiol 213:412-419.
20. Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kaminski N, Benos PV. 2009. Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PloS ONE 4:e5279.
21. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R. 1998. P53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis. Blood 91:4342-4349.
22. Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, Molina JR, Carlotti C, Jr., Tirapelli D, Neder L, Brassesco MS, Scrideli CA, Tone LG, Georgescu MM, Zhang W, Puduvalli V, Calin GA. 2010. MiR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 49:981-990.
23. Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG. 2009. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 11:1208-1215.
24. Demchenko YN, Kuehl WM. 2010. A critical role for the NFkB pathway in multiple myeloma. Oncotarget 1:59-68.
25. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. 2008. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 7:2643-2646.
26. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gulla A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P. 2012. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence. Clin Cancer Res 18:6260-6270.
27. Di Martino MT, Gulla A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P. 2013. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 4:242-255.
28. Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F. 2013. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle 13:652-665.
29. Elnenaei MO, Gruszka-Westwood AM, A'Hernt R, Matutes E, Sirohi B, Powles R, Catovsky D. 2003. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Haematologica 88:529-537.
30. Erster S, Moll UM. 2004. Stress-induced p53 runs a direct mitochondrial death program: its role in physiologic and pathophysiologic stress responses in vivo. Cell Cycle 3:1492-1495.
31. Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux P, Vanrumbeke M, Sartiaux C, Morel P, Loucheux-Lefebvre MH, Bauters F. 1992. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 6:246-250.
32. Feng Z, Hu W, Rajagopal G, Levine AJ. 2008. The tumor suppressor p53: Cancer and aging. Cell Cycle 7:842-847.
33. Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, Di Rocco C, Riccardi R, Giangaspero F, Farcomeni A, Nofroni I, Laneve P, Gioia U, Caffarelli E, Bozzoni I, Screpanti I, Gulino A. 2009. MicroRNA profiling in human medulloblastoma. Int J Cancer 124:568-577.
34. Fulciniti M, Amodio N, Bandi RL, Munshi M, Yang G, Xu L, Hunter Z, Tassone P, Anderson KC, Treon SP, Munshi NC. 2014. MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood 123:2673-2681.
35. Garzon R, Marcucci G, Croce CM. 2010. Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov 9:775-789.
36. Gerrits A, Walasek MA, Olthof S, Weersing E, Ritsema M, Zwart E, van Os R, Bystrykh LV, de Haan G. 2012. Genetic screen identifies microRNA cluster 99b/let-7e/125a as a regulator of primitive hematopoietic cells. Blood 119:377-387.
37. Giono LE, Manfredi JJ. 2006. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 209:13-20.
38. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, Ferminan E, Martin-Jimenez P, Chillon C, Risueno A, Hernandez JM, Garcia-Sanz R, Gonzalez M, San Miguel JF. 2010. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 24:629-637.
39. Hao M, Zhang L, An G, Sui W, Yu Z, Zou D, Xu Y, Chang H, Qiu L. 2011. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol 4:37.
40. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. P53 mutations in human cancers. Science 253:49-53.
41. Jiang L, Huang Q, Chang J, Wang E, Qiu X. 2011. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp Lung Res 37:387-398.
42. Jiang L, Chang J, Zhang Q, Sun L, Qiu X. 2013. MicroRNA hsa-miR-125a-3p activates p53 and induces apoptosis in lung cancer cells. Cancer Invest 31:538-544.
43. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. 2012. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA 109:7865-7870.
44. Kong W, Zhao JJ, He L, Cheng JQ. 2009. Strategies for profiling microRNA expression. J Cell Physiol 218:22-25.
45. Kumar A, Jeang KT. 2008. Insights into cellular microRNAs and human immunodeficiency virus type 1 (HIV-1). J Cell Physiol 216:327-331.
46. Kupper M, Joos S, von Bonin F, Daus H, Pfreundschuh M, Lichter P, Trumper L. 2001. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: Results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 112:768-775.
47. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gulla A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. 2013. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 19:2096-2106.
48. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. 2005. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433:769-773.
49. Lin CP, Choi YJ, Hicks GG, He L. 2012. The emerging functions of the p53-miRNA network in stem cell biology. Cell Cycle 11:2063-2072.
50. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S, Lombardi L, Bortoluzzi S, Neri A. 2009. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 114:e20-e26.
51. Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omede P, Morabito F, Tassone P, Boccadoro M, Palumbo A, Neri A. 2013. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res 19:3130-3142.
52. Long YS, Deng GF, Sun XS, Yi YH, Su T, Zhao QH, Liao WP. 2011. Identification of the transcriptional promoters in the proximal regions of human microRNA genes. Mol Biol Rep 38:4153-4157.
53. Lu M, Hoffman R. 2012. P53 as a target in myeloproliferative neoplasms. Oncotarget 3:1052-1053.
54. Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. 2012. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012:157496.
55. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. 2006. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24.
56. Mendell JT. 2005. MicroRNAs: Critical regulators of development, cellular physiology and malignancy. Cell Cycle 4:1179-1184.
57. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I. 2006. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126:1203-1217.
58. Mitani N, Niwa Y, Okamoto Y. 2007. Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem 44:557-559.
59. Morgan GJ, Walker BA, Davies FE. 2012. The genetic architecture of multiple myeloma. Nat Rev Cancer 12:335-348.
60. Munshi NC, Anderson KC. 2013. New strategies in the treatment of multiple myeloma. Clin Cancer Res 19:3337-3344.
61. Murray MY, Rushworth SA, Zaitseva L, Bowles KM, Macewan DJ. 2013. Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle 12:2144-2153.
62. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. 1993. P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81:128-135.
63. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, Ventura M, Eramo PO, Viscomi C, Arbitrio M, Rossi M, Caraglia M, Munshi NC, Anderson KC, Tassone P. 2008. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 143:520-531.
64. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. 2011. Proteotoxic stress targeted therapy (PSTT): Induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2:209-221.
65. Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. 2014. Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 7:127-141.
66. Olena AF, Patton JG. 2010. Genomic organization of microRNAs. J Cell Physiol 222:540-545.
67. Oren M. 2003. Decision making by p53: Life, death and cancer. Cell Death Differ 10:431-442.
68. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM. 2008. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 105:12885-12890.
69. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Jr., Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM. 2010. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18:367-381.
70. Pinto R, Pilato B, Ottini L, Lambo R, Simone G, Paradiso A, Tommasi S. 2013. Different methylation and microRNA expression pattern in male and female familial breast cancer. J Cell Physiol 228:1264-1269.
71. Potenza N, Russo A. 2013. Biogenesis, evolution and functional targets of microRNA-125a. Mol Genet genomics 288:381-389.
72. Potenza N, Papa U, Mosca N, Zerbini F, Nobile V, Russo A. 2011. Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res 39:5157-5163.
73. Pritchard CC, Cheng HH, Tewari M. 2012. MicroRNA profiling: Approaches and considerations. Nat Rev Genet 13:358-369.
74. Raver-Shapira N, Oren M. 2007. Tiny actors, great roles: MicroRNAs in p53's service. Cell Cycle 6:2656-2661.
75. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. 2004. Identification of mammalian microRNA host genes and transcription units. Genome Res 14:1902-1910.
76. Rossi M, Amodio N, Di Martino MT, Caracciolo D, Tagliaferri P, Tassone P. 2013a. From target therapy to miRNA therapeutics of human multiple myeloma: Theoretical and technological issues in the evolving scenario. Curr Drug targets 14:1144-1149.
77. Rossi M, Botta C, Correale P, Tassone P, Tagliaferri P. 2013b. Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opin Biol Ther 13:S83-S93.
78. Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, Botta C, Paolino FM, Del Giudice T, Iuliano E, Caraglia M, Ferrarini M, Giordano A, Tagliaferri P, Tassone P. 2013c. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. Expert Opin Biol Ther 228:1506-1515.
79. Saha MN, Qiu L, Chang H. 2013. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 6:23.
80. Sherman MY. 2011. Proteotoxic stress targeted therapy (PSTT). Oncotarget 2:356-357.
81. Subramanian S, Steer CJ. 2010. MicroRNAs as gatekeepers of apoptosis. J Cell Physiol 223:289-298.
82. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A, Tassone P. 2012. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 12:838-846.
83. Tai YT, Anderson KC. 2012. Bruton's tyrosine kinase: Oncotarget in myeloma. Oncotarget 3:913-914.
84. Tassone P, Tagliaferri P. 2012. Editorial: New approaches in the treatment of multiple myeloma: From target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta). Curr Cancer Drug Targets 12:741-742.
85. Tassone P, Neri P, Kutok JL, Tournilhac O, Santos DD, Hatjiharissi E, Munshi V, Venuta S, Anderson KC, Treon SP, Munshi NC. 2005. A SCID-hu in vivo model of human Waldenstrom macroglobulinemia. Blood 106:1341-1345.
86. Tassone P, Tagliaferri P, Rossi M, Gaspari M, Terracciano R, Venuta S. 2006. Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management?. Eur J Cancer 42:1530-1538.
87. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia M, Tagliaferri P. 2009. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 8:648-653.
88. Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, Caraglia M, Tagliaferri P. 2012. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets 12:814-822.
89. Tsang J, Zhu J, van Oudenaarden A. 2007. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell 26:753-767.
90. Vimalraj S, Partridge NC, Selvamurugan N. 2014. A positive role of microRNA-15b on regulation of osteoblast differentiation. J Cell Physiol [Epub ahead of print].
91. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310.
92. Wang XW, Harris CC. 1997. P53 tumor-suppressor gene: Clues to molecular carcinogenesis. J Cell Physiol 173:247-255.
93. Wang Y, Keys DN, Au-Young JK, Chen C. 2009. MicroRNAs in embryonic stem cells. J Cell Physiol 218:251-255.
94. Weber B, Stresemann C, Brueckner B, Lyko F. 2007. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 6:1001-1005.
95. Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ. 2013. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol 162:348-359.
96. Zhang B, Wang Q, Pan X. 2007. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol 210:279-289.
97. Zhang Y, Gao JS, Tang X, Tucker LD, Quesenberry P, Rigoutsos I, Ramratnam B. 2009. MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett 583:3725-3730.
98. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, Pineda-Roman M, Alsayed Y, Anaissie E, Shaughnessy JD, Jr. 2010. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 107:7904-7909.